Neglected Tropical Disease Treatment Market By Treatment Type (Preventive Chemotherapy, Disease-Specific Pharmacotherapy, Supportive and Morbidity Management Care, Hospital-Based Acute Care, Pediatric and Field-Ready Formulations); By Disease Type (Lymphatic Filariasis, Onchocerciasis, Schistosomiasis, Soil-Transmitted Helminth Infections, Trachoma, Leprosy, Dengue, Chagas Disease, Leishmaniasis, Human African Trypanosomiasis, Rabies, Snakebite Envenoming, Others); By Access Model (Mass Drug Administration, Donation-Backed Access, Public Procurement, Community Health Delivery, Hospital and Referral-Based Treatment, Diagnostics-Linked Treatment Access); By End User (National NTD Programmes, Public Health Agencies, Hospitals and Referral Centers, NGOs and Implementation Partners, Donor Agencies, Community Health Networks); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Neglected Tropical Disease Treatment Market: Mass Drug Administration, Donation-Backed Access, and Human Rights Policy Reframe Global Demand

The Global Neglected Tropical Disease Treatment Market is projected to grow at a CAGR of 5.9%, expanding from USD 3.87 billion in 2025 to USD 5.78 billion by 2032, according to Strategic Market Research.

 

Neglected tropical disease treatment operates as a public-health delivery market rather than a conventional branded pharmaceutical category. Demand is measured through people requiring interventions, donated medicine flows, mass drug administration coverage, diagnostics procurement, national elimination campaigns, and donor-backed delivery capacity. WHO estimates that more than 1 billion people are affected by NTDs, while 1.495 billion people require preventive or curative interventions every year. NTDs also cause about 120,000 deaths and 14.1 million disability-adjusted life years annually, alongside major losses from health spending, disability, lost productivity, stigma, and social exclusion.

 

WHO’s 2030 roadmap has delivered measurable gains, although programme pressure is rising. WHO’s 2025 global NTD report states that 1.495 billion people required interventions in 2023, down 122 million from 2022 and 32% below the 2010 baseline. In the same year, 867.1 million people were treated for at least one NTD, with 99% receiving preventive chemotherapy. NTD-related disease burden fell from 17.2 million DALYs in 2015 to 14.1 million in 2021, while estimated deaths declined from 139,000 to 119,000. Controlled settings are reducing treatment need, but remaining endemic communities are harder to reach, more rural, more conflict-exposed, and more dependent on stable donor logistics.

 

Public Procurement and Donations Shape Treatment Access

NTD treatment depends on public-health procurement, medicine donation, and field delivery rather than routine retail prescribing. WHO-supported access programmes rely on manufacturers, development partners, national health ministries, community distributors, diagnostics suppliers, and surveillance platforms. By the end of 2024, 12 manufacturers had donated 19 different types of NTD medicines, and almost 30 billion tablets and vials had been delivered to countries during 2011–2024, including 1.8 billion for treatments in 2024 alone. WHO also facilitated procurement of more than 1 million diagnostic tests in 2024 for five NTDs.

Low-cost medicines can generate substantial public health value when supported by delivery systems capable of reaching populations at scale. The CDC estimates that treatment for most neglected tropical disease mass drug administration programs can cost less than USD 0.50 per person annually. For manufacturers, these programs create value through expanded access, stronger public health credibility, regulatory goodwill, and partnership opportunities. For governments and donors, they support measurable progress toward disease elimination targets, while communities benefit from reduced infection burden, disability, stigma, and long-term productivity losses.

WHO’s 2030 targets set the operating framework for national programmes: a 90% reduction in people requiring NTD interventions, a 75% reduction in NTD-related DALYs, at least 100 countries eliminating at least one NTD, and eradication of dracunculiasis and yaws. National programmes are therefore moving toward integrated delivery models that combine preventive chemotherapy, case management, vector control, veterinary public health, WASH, diagnostics, and surveillance. Suppliers with support for last-mile logistics, campaign monitoring, and data reporting have stronger relevance than medicine-only participants.

 

Preventive Chemotherapy Delivers the Largest Treatment Volume

Preventive chemotherapy remains the highest-volume treatment segment because lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminths, and trachoma require repeated community-level treatment. Campaigns generate large tablet demand, but funding and delivery systems determine whether donated or procured medicines reach target populations. WHO’s 2025 report recorded 867.1 million people treated for at least one NTD in 2023, with preventive chemotherapy accounting for nearly all treatments.

Lymphatic filariasis remains one of the largest preventive chemotherapy categories. WHO states that more than 657 million people in 39 countries remain threatened by lymphatic filariasis and require preventive chemotherapy. Annual mass drug administration supports transmission control, while morbidity management for lymphoedema and hydrocele requires disability care, surgery referral, community education, adverse-event monitoring, and post-MDA surveillance.

Onchocerciasis treatment remains concentrated in Africa and Yemen. WHO reports that more than 99% of infected people live in Africa and Yemen, and at least 252.3 million people required preventive treatment in 2024. Ivermectin treatment reached 171.6 million people in 2024. River blindness programmes depend on sustained ivermectin supply, community-directed treatment, therapeutic coverage, cross-border coordination, and surveillance to prevent transmission rebound.

Schistosomiasis creates large demand for praziquantel, especially among school-age children. WHO estimates that at least 253.7 million people required preventive treatment in 2024, while more than 100.5 million were reported to have been treated. WHO data also show that 134.8 million school-age children needed preventive chemotherapy in 2024. Praziquantel demand is closely tied to WASH, snail control, veterinary public health, and repeated coverage in lakeside, irrigation, fishing, and farming communities.

Soil-transmitted helminth infections keep deworming programmes central to NTD treatment. WHO estimates that 1.5 billion people, or 24% of the global population, are infected. School-based deworming, maternal health platforms, adolescent health programmes, and community campaigns drive demand for albendazole and mebendazole. Coverage gaps persist where school attendance, sanitation, health staffing, and routine community outreach remain weak.

Trachoma treatment is moving from broad campaigns toward targeted elimination support in countries approaching public-health control. WHO reported that 87,349 people received surgery for advanced disease in 2024, while 44.4 million people were treated with antibiotics; global antibiotic coverage was 39%. Australia’s 2026 validation as the 30th country to eliminate trachoma as a public health problem reflects long-term investment in surgery, antibiotics, facial cleanliness, environmental improvement, surveillance, and community-level prevention.

 

Case-Managed NTDs Need Diagnostics, Referral, and Shorter Regimens

Case-managed NTDs generate smaller treatment volumes but greater clinical complexity. Leprosy, Chagas disease, leishmaniasis, human African trypanosomiasis, mycetoma, noma, snakebite envenoming, rabies, dengue, and yaws require diagnosis, referral, laboratory confirmation, clinical monitoring, and in some cases hospital-level care. Product suitability for remote settings, pediatric formulations, supply reliability, diagnostic availability, and clinician training shape treatment access in this segment.

Leprosy remains curable but persistent. WHO reported 172,717 new leprosy cases in 2024 across 188 countries, areas, and territories, including 9,397 children and 9,157 people with grade-2 disability at diagnosis. Multidrug therapy has been provided free through WHO since 1995, and more than 17 million patients have received MDT over the past four decades. Early diagnosis, contact tracing, post-exposure prophylaxis, disability prevention, stigma reduction, and sustained MDT supply now define the treatment need more than discovery of a first-line drug.

Dengue is becoming the most visible therapeutic gap within the NTD landscape. WHO states that reported dengue cases increased from 505,430 in 2000 to 14.6 million in 2024, while dengue is now endemic in more than 100 countries. No specific treatment exists for dengue or severe dengue, leaving clinical management, warning-sign detection, fluid support, hospital care, vector control, diagnostics, vaccines, and future antivirals as the main response areas.

Visceral leishmaniasis, Chagas disease, and human African trypanosomiasis remain difficult to treat at scale because existing medicines often require diagnosis, monitoring, and delivery capacity that many endemic settings lack. WHO and Gilead renewed a five-year partnership for 2026–2030 to support visceral leishmaniasis elimination through donated medicines and funding support. Gilead states that visceral leishmaniasis remains a public-health challenge with an estimated 50,000 to 90,000 new cases each year. Product donation helps only when surveillance, case detection, referral, and treatment delivery remain funded.

 

Funding Cuts Are Disrupting Treatment Delivery

NTD programmes lose effectiveness when funding stops, even when medicines are donated. WHO warned in June 2025 that U.S. funding withdrawal delayed 47 campaigns intended to free 143 million people from NTD burden. Missed campaigns and impact surveys in 2025 were expected to postpone target achievement in at least 10 additional countries. Field staff, transport, warehousing, supervision, community distributors, and post-campaign surveys determine whether donated medicines reach people before expiry.

U.S. support had been central to global delivery scale. WHO reported that USAID-supported NTD work delivered 3.3 billion treatments to more than 1.7 billion people in 26 countries, backed by cumulative support of US$1.4 billion. That funding helped 14 countries eliminate at least one NTD. WHO also warned that more than 55 million NTD tablets could expire in Africa alone by the end of 2025 without alternative delivery mechanisms. Medicine availability no longer guarantees treatment access when programme financing collapses.

Official development assistance pressure extends beyond a single donor. WHO’s 2025 global report states that NTD programmes continue to be disrupted by reduced funding and that official development assistance for NTDs decreased 41% between 2018 and 2023. WHO’s World NTD Day 2026 campaign used the same 41% decline as a headline risk while noting that 1.4 billion people still required NTD interventions. Last-mile elimination programmes face higher per-person delivery costs as remaining cases become harder to find and treat.

 

Human Rights Policy Broadens Treatment Requirements

The July 2026 UN Human Rights Council resolution expands NTD treatment from medicine supply toward integrated access delivery. Resolution 62/27 links NTD control with health, WASH, housing, education, information access, stigma reduction, and non-discrimination. National programmes will need stronger links between treatment, diagnostics, disability care, surveillance, social support, and community-based services.

Governments, donors, and implementation partners face higher programme expectations under the rights-based framework. Drug-only campaigns will underperform where diagnosis, adherence, reinfection control, patient follow-up, disability care, and stigma reduction remain weak. Integrated suppliers and service providers can gain relevance by supporting treatment delivery, mental health screening, referral systems, WASH-linked interventions, field data reporting, and community participation.

WHO’s 2026 mental health care package adds patient-support services to NTD programme design. Mental health and stigma reduction can improve treatment adherence, earlier diagnosis, and retention in care. Community health workers, digital monitoring tools, referral networks, and integrated care platforms will become more relevant where NTDs cause disability, disfigurement, social exclusion, and long-term psychological distress.

 

Pharmaceutical Partnerships Sustain the Access Model

Pharmaceutical donations remain the backbone of NTD medicine access. WHO noted that donations from Bayer, Chemo Group, Eisai, EMS SA Pharma, Gilead, GSK, Johnson & Johnson, Merck KGaA, MSD, Novartis, Pfizer, and Sanofi were cumulatively valued at more than US$12 billion from 2011 to 2025. These partnerships keep medicines available at minimal cost, while countries and donors still need to fund diagnostics, logistics, data systems, trained field workers, and surveillance.

Bayer’s NTD portfolio supports case-managed diseases where donated medicines remain essential. WHO and Bayer renewed their collaboration in November 2025 to support free treatment for Chagas disease, human African trypanosomiasis, and selected helminth infections. Bayer’s nifurtimox donation began in 2004, and the pediatric 30 mg formulation introduced since 2020 improved treatment uptake among children with Chagas disease. Bayer also states that it has donated suramin for rhodesiense sleeping sickness since 2002 and nifurtimox for nifurtimox-eflornithine combination therapy since 2009.

Eisai remains important in lymphatic filariasis elimination through diethylcarbamazine. The company received WHO prequalification for DEC 100 mg tablets in 2013, the first WHO prequalification for a medicine used to treat an NTD. Eisai has committed to providing DEC tablets free to endemic countries until lymphatic filariasis is eliminated. DEC supply supports mass drug administration in countries where the regimen is appropriate, while the company’s India manufacturing base adds regional relevance to global supply.

Novartis is using global health R&D to strengthen its long-term access position. The company’s 2026–2030 social impact targets include at least US$250 million for R&D in malaria and NTDs over five years. Reuters reported in 2025 that Novartis planned to spend about US$490 million on malaria and NTD R&D by the end of 2025, compared with an earlier US$250 million pledge. Programmes cited include dengue antiviral work, leishmaniasis, Chagas disease, and malaria treatment for newborns.

 

R&D Is Prioritizing Field-Ready Treatment

NTD innovation creates the most value when it reduces operational burden in low-resource settings. New products must work where laboratory capacity, cold-chain reliability, specialist staffing, transport, and follow-up are limited. WHO’s 2025 report noted technical progress in 2024, including six new prequalified medicine formulations, one active pharmaceutical ingredient, one dengue vaccine, and six target product profiles that brought the total to 27. Affordability, heat stability, shorter regimens, pediatric suitability, fewer monitoring requirements, and primary-care delivery will determine which products gain practical adoption.

Acoziborole offers the clearest recent example of operationally useful innovation. DNDi and Sanofi announced in February 2026 that Acoziborole Winthrop received a positive EMA scientific opinion as a three-tablet, single-dose oral treatment for gambiense sleeping sickness. DNDi describes acoziborole as the first single-dose oral treatment for both stages of T.b. gambiense sleeping sickness, with potential to support village-level treatment and elimination by 2030. A single-dose oral regimen could reduce hospitalization, invasive staging, infusion logistics, and treatment abandonment in remote endemic areas.

Dengue treatment R&D is gaining urgency as outbreaks outpace supportive-care capacity. DNDi and the Serum Institute of India announced in July 2026 that Brazil, Malaysia, and Thailand were set to start a global clinical trial for a promising dengue treatment developed by Serum Institute. The collaboration builds on a 2025 MoU to accelerate an affordable monoclonal antibody treatment for dengue in low- and middle-income countries. Successful dengue therapeutics could shift part of the response from hospital-based fluid management toward targeted treatment for patients at risk of progression.

Drug repurposing and computational discovery are being used to reduce R&D cost and timeline. A 2026 Frontiers in Pharmacology review notes that repurposing has added treatment options for NTDs, while drug resistance remains a major hurdle. Access-focused innovation will continue to depend on product development partnerships, public funding, academic platforms, local trial capacity, and manufacturer participation because most affected populations cannot support high-price commercial development.

 

Africa, South Asia, and Latin America Drive Regional Treatment Demand

Africa remains the largest NTD treatment region and the most exposed to programme disruption. More than 99% of people infected with onchocerciasis live in Africa and Yemen. At least 252.3 million people required preventive treatment for onchocerciasis in 2024. Schistosomiasis remains heavily concentrated in sub-Saharan Africa, where repeated praziquantel campaigns are required in school-age children and high-risk adults. Lymphatic filariasis elimination programmes continue across multiple African countries, but coverage depends on annual mass drug administration and community delivery networks. East African visceral leishmaniasis programmes require laboratory diagnosis, referral systems, inpatient capacity, and reliable access to amphotericin-based or oral treatment regimens. Funding cuts have a disproportionate effect in Africa because donated medicines cannot be deployed without transport, trained distributors, supervision, and post-treatment surveillance.

South Asia and Southeast Asia combine high-volume preventive chemotherapy with complex case-managed diseases. India carries major burdens of lymphatic filariasis, soil-transmitted helminth infections, leprosy, dengue, rabies, and visceral leishmaniasis. India also reported more than half of the world’s new leprosy cases in recent WHO reporting. Large school-based deworming programmes and elimination campaigns create demand for DEC, albendazole, praziquantel, multidrug therapy for leprosy, and dengue diagnostics. India’s medicine and biologics manufacturing capacity strengthens regional supply security when linked with national elimination programmes and public procurement systems. Serum Institute’s dengue antibody programme with DNDi and Eisai’s DEC production history show how local manufacturing can support global access.

Latin America faces rising treatment demand from dengue, Chagas disease, leishmaniasis, cysticercosis, and snakebite envenoming. Dengue is the dominant acute-care pressure point, with the Americas accounting for a major share of the 2024 global surge. Brazil remains the region’s largest dengue market and also carries substantial Chagas disease and leishmaniasis burdens. Chagas treatment depends on early diagnosis and access to benznidazole or nifurtimox before irreversible cardiac or gastrointestinal complications develop. Dengue outbreaks create demand for diagnostics, hospital triage, fluid management, vector control, vaccines, and future antiviral or monoclonal antibody therapies. Climate change, urban expansion, and Aedes mosquito spread are shifting the region toward emergency preparedness and scalable outpatient treatment pathways.

 

Analyst View

Neglected tropical disease treatment remains a high-volume public-health market with non-traditional economics. Preventive chemotherapy delivers the largest treatment volume, case-managed diseases carry the highest clinical complexity, and dengue presents the most urgent therapeutic gap. Medicine donations remain essential, but access breaks down when logistics, community distribution, diagnostics, health workers, and surveillance lose funding.

Mass drug administration will remain the main treatment channel for lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminths, and trachoma. Case-managed diseases will attract more R&D investment where shorter regimens, pediatric formulations, point-of-care diagnostics, and simplified treatment can reduce delivery cost. Acoziborole, pediatric nifurtimox, dengue antibody development, DEC donation, and leishmaniasis partnerships show how product design must match field realities.

Programme performance should be tracked through people requiring interventions, preventive chemotherapy coverage, donated medicine volume, diagnostic procurement, ODA stability, country elimination validations, dengue case trends, treatment-center capacity, and funding continuity for last-mile campaigns. Suppliers and partners that combine affordable products with delivery support, diagnostics, data systems, and country-owned implementation will hold stronger positions than groups focused only on medicine supply.

 

Neglected Tropical Disease Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.87 Billion
Revenue Forecast in 2032	USD 5.78 Billion
Overall Growth Rate	CAGR of 5.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Disease Type, By Access Model, By End User, By Geography
By Treatment Type	Preventive Chemotherapy, Disease-Specific Pharmacotherapy, Supportive and Morbidity Management Care, Hospital-Based Acute Care, Pediatric and Field-Ready Formulations
By Disease Type	Lymphatic Filariasis, Onchocerciasis, Schistosomiasis, Soil-Transmitted Helminth Infections, Trachoma, Leprosy, Dengue, Chagas Disease, Leishmaniasis, Human African Trypanosomiasis, Rabies, Snakebite Envenoming, Others
By Access Model	Mass Drug Administration, Donation-Backed Access, Public Procurement, Community Health Delivery, Hospital and Referral-Based Treatment, Diagnostics-Linked Treatment Access
By End User	National NTD Programmes, Public Health Agencies, Hospitals and Referral Centers, NGOs and Implementation Partners, Donor Agencies, Community Health Networks
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Growing global elimination programmes, expansion of mass drug administration initiatives, pharmaceutical donation partnerships, rising demand for field-ready treatments, increased focus on integrated healthcare delivery, improved diagnostics and surveillance systems
Customization Option	Available upon request